HAMBURG, GERMANY / ACCESSWIRE / October 30, 2024 / Evotec SE (Frankfurt Inventory Change:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) will announce its monetary outcomes for the primary 9 months of 2024 on Wednesday, 06 November 2024.
The Firm goes to carry a convention name to debate 9-months outcomes in addition to to offer an outline on the continuing precedence reset and the strategic evaluation course of. The convention name will likely be held in English.
Webcast particulars
Date: Wednesday, 06 November 2024
Time: 2.00 pm CET (01.00 pm GMT, 08.00 am EST)
To affix the audio webcast and to entry the presentation slides, please register through this hyperlink.
The on-demand model of the webcast will likely be accessible on our web site: www.evotec.com/en/investor-relations/financial-publications.
Convention name particulars
To affix through telephone, please pre-register through this hyperlink. You’ll then obtain a affirmation electronic mail with devoted dial-in particulars reminiscent of phone quantity, entry code and PIN to entry the decision.
A simultaneous slide presentation for members dialling in through telephone is out there underneath this hyperlink.
About Evotec SE
Evotec is a life science firm with a novel enterprise mannequin that delivers on its mission to find and develop extremely efficient therapeutics and make them accessible to the sufferers. The Firm’s multimodality platform includes a novel mixture of revolutionary applied sciences, knowledge and science for the invention, growth, and manufacturing of first-in-class and best-in-class pharmaceutical merchandise. Evotec supplies excessive worth pipeline co-creating partnerships and options to all Prime 20 Pharma and over 800 biotechnology corporations, tutorial establishments, in addition to different healthcare stakeholders. Evotec has strategic actions in a broad vary of at present underserved therapeutic areas, together with e.g. neurology, oncology, in addition to metabolic and infectious illnesses. Inside these areas of experience, Evotec goals to create the world-leading co-owned pipeline for revolutionary therapeutics and has to-date established a portfolio of greater than 200 proprietary and co-owned R&D tasks from early discovery to medical growth. Evotec operates globally with greater than 5,000 extremely certified folks. The Firm’s websites in Europe and the USA provide extremely synergistic applied sciences and providers and function as complementary clusters of excellence. For added info please go to www.evotec.com and comply with us on X/Twitter @Evotec and LinkedIn.
Ahead-looking statements
This announcement incorporates forward-looking statements regarding future occasions, together with the proposed providing and itemizing of Evotec’s securities. Phrases reminiscent of “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such phrases and related expressions are supposed to determine forward-looking statements. Such statements embrace feedback relating to Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D bills. These forward-looking statements are based mostly on the knowledge accessible to, and the expectations and assumptions deemed cheap by Evotec on the time these statements had been made. No assurance might be on condition that such expectations will show to have been appropriate. These statements contain recognized and unknown dangers and are based mostly upon quite a few assumptions and estimates, that are inherently topic to vital uncertainties and contingencies, a lot of that are past the management of Evotec. Evotec expressly disclaims any obligations or enterprise to launch publicly any updates or revisions to any forward-looking statements contained herein to mirror any change in Evotec’s expectations with respect thereto or any change in occasions, situations or circumstances on which any assertion relies.
IR Contact Evotec SE:
Volker Braun, EVP Head of International Investor Relations & ESG, Volker.Braun@evotec.com
SOURCE: Evotec SE
View the unique press launch on accesswire.com
